nature jobs.com - the premier science recruitment website

NPG's BioPartnering is dedicated to small and large companies looking for commercial partnerships and finding out more about licensing. Find executive profiles from companies actively looking for partners.

BioPharma Dealmakers

At Merck, we are strongly committed to partnership success. We recognize that the greatest achievements are not reached alone. They are the result of teamwork. We are serious about our commitment to strategic alliances. Our goal is to work together with our partners to remain in the forefront of turning scientific breakthroughs into medicines that make a difference. We have established a clear path to partnering, and we invite you to explore the combining of your strengths with ours, and the successes we may share.

Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, is seeking partners who will share in the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allows us to collaborate effectively with a broad array of partners around the would. We are not only at the forefront of conquering newly targeted diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

Hugh Cowley leads The Center of Excellence for External Drug Discovery (CEEDD) at GSK. This dedicated R&D unit is tasked to build and deliver an entirely external portfolio of highly innovative drug discovery programs through risk-sharing alliances with world-class biotechnology companies. Hugh talks about how his group builds alliances which encourage innovation, yet maintain independence.

Novo Nordisk seeks partners to increase its promising, protein-based pipeline within diabetes, haemostasis and chronic inflammation. Novo Nordisk masters all aspects of bringing proteins from molecule to market, and employs more than 25,000 staff in 79 countries worldwide.

 
 

The Health Protection Agency's core business areas are research and development of vaccines against infectious diseases, process development and GMP manufacture of biologics. In addition, a wide range of support services are offered from biosafety, through GLP immunoassay testing to in vivo studies.

BTG in-licenses, develops and commercialises pharmaceuticals. Principally in the field of neuroscience but also in other areas. The company has a substantial and growing revenue stream of royalties from out licensed products and a broad, expanding internal pipeline of development programmes. This company is evolving towards growing a later stage pipeline, eventually aiming to take niche products to market. This will be funded by milestones and royalties from partnered programs, including two projects in Phase III and seven in Phase II.

Affitech discovers and develops fully human antibody therapeutics for both partners, such as Roche and Peregrine, and its own pipeline with a primary focus in oncology. Headquartered in Oslo, Norway with business development in San Francisco, California, Affitech uses two proprietary discovery technologies - MBAS (molecule based) and CBAS(cell based). By discovering both antibody and target simultaneously from patient libraries CBAS shortens development times by up to two years.

Palau Pharma, S.A. ("Palau") is a product-driven biopharmaceutical company applying its expertise to the discovery and development of innovative, better and safer small-molecule drug candidates to treat inflammatory and autoimmune diseases. The Company’s current strategy is to develop its compounds through Phase II clinical development, at which point Palau will decide on a case-by-case basis to either keep the development in-house, or to partner or license out for late-stage development and commercialization.

Q-Chip's proprietary MicroPlant system for biological packaging and stabilisation, best imagined as Tetra Pak on a very small scale, is available to license for multiple applications in molecular diagnostics and pharmaceutical markets.

P&G Pharmaceuticals offers potential partners the best of both worlds: the unique insights and marketing expertise of the world's largest consumer products company and also the personal touch of a focused pharmaceutical company that's small enough to give each development project and marketed product the attention it deserves.

Sidec offers collaborative research to better select, protect and market therapeutic antibodies and other biotherapeutics. Clients are big pharma as well as biotechnology companies. Sidec AB is a rapidly growing, Swedish company providing collaborative research based on its proprietary technology, Protein Tomography™, and expertise in characterization of biologicals. Protein Tomography™ studies add unique value in biological candidate discovery, for IP protection and in marketing.

Debiopharm is a financially independent drug development company based in Lausanne, Switzerland, that in-licenses promising therapeutic compounds, develops them globally and then out-licenses them for commercialization. By concentrating only on the development of products rather than on external investors and sales and marketing, Debiopharm has become a highly successful developer.

VIA Pharmaceuticals, Inc. is a biotechnology company located in San Francisco, California, which is focused on the development of therapeutics for the treatment of cardiovascular disease. Its lead compound, VIA-2291, is currently in Phase II clinical trials in North America and Europe. It targets inflammation in the blood vessel, the underlying cause of cardiovascular disease.

Partnering Features

  • Avoiding premature licensing
    • Nature Reviews Drug Discovery
    • From the analyst's couch.
  • The "not invented here" myth
    • Nature Reviews Drug Discovery
    • From the analyst's couch.
  • Drug approvals and failures: implications for alliances
    • Nature Reviews Drug Discovery
    • Could more partnering between biotech and pharma companies help reduce late-stage attrition?
  • Minimizing leakage of value from R&D alliances
    • Nature Reviews Drug Discovery
    • This article summarize recent trends in alliance formation and discuss approaches to minimize risk in alliances, which are growing in importance as alliance activity increases.
  • Leveraging your biotech intellectual property
    • Bioentrepreneur
    • Biotech companies can extract unexpected value from their patent portfolios to remove roadblocks on the path to commercialization and success.
  • Learning from each other
    • Bioentrepreneur
    • An industry academic liaison officer and a university technology-transfer professional in the UK canvass their peers to provide some pointers for how to streamline the technology-transfer process between companies and academia.
  • Best practices in patent license negotiations
    • Bioentrepreneur
    • There's a lot to consider before out-licensing patent rights. Here, a law student and a seasoned patent attorney outline what every bioentrepreneur should know before tackling the task.
  • Getting dumped
    • Bioentrepreneur
    • What to do when your licensed product is returned.
  • What pharma wants
    • Bioentrepreneur
    • Pharma has pipelines to fill and cash to spend. But just what types of partners and products is it looking for?
  • The MTA—rip it up and start again?
    • Nature Biotechnology
    • Securing material transfer agreements can be burdensome for academics and make downstream research prohibitively expensive, particularly for small startups with limited resources. Two technology-transfer professionals debate the pros and cons of such contracts.
  • Licensing deals morph to acquisitions in seller's market
    • Nature Biotechnology
    • Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions.
  • The global stem cell patent landscape: implications for efficient technology transfer and commercial development
    • Nature Biotechnology
    • Characteristics of the complex and growing stem cell patent landscape indicate strategies by which public sector research institutions could improve the efficiency of intellectual property.
  • Research sharing, ethics and public benefit
    • Nature Biotechnology
    • Other areas of biomedical research should emulate new standards from the International Society for Stem Cell Research highlighting the importance of sharing materials, data and research rights, and requiring fair global access to resulting diagnostics and therapies.
  • Negotiating the RNAi patent thicket
    • Nature Biotechnology
    • Patent disputes haven't materialized in the RNAi field yet, but once products near the market, it might be a different story. Charlie Schmidt investigates.
  • Gold in the ivory tower: equity rewards of outlicensing
    • Nature Biotechnology
    • An analysis of life-science initial public offerings from three time periods reveals that the equity share received by universities and their academic researchers has changed over time.

No Guts No Glory
When the going get's tough, the tough get going! In this article from the June'08 Licensing Executive Profiles, freelance journalist Crispin Littlehales interviews some of the industry's leading Dealmakers. Through this we see some of the most courageous partnering strategies from the major players, giving insight into how the marketplace is shaping up.

Download Article

 

 

Let's make a Deal
In this article from the October'07 Licensing Executive Profiles, freelance journalist Crispin Littlehales analyzes the global biopartnering marketplace. Here you can glean insight from some of the most prolific biopartnering deal makers, who indicate what it is the major pharmaceutical and biotech companies are looking for from potential biotech collaborators.

Download Article

 

 

ADVERTISEMENT